Amicus Therapeutics Inc
(MEX:FOLD)
MXN
208.8
0 (0%)
Market Cap: 60.68 Bil
Enterprise Value: 64.66 Bil
PE Ratio: 0
PB Ratio: 16.63
GF Score: 78/100 Amicus Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 12, 2019 / 12:00PM GMT
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
Well, good morning, everyone. It's my distinct pleasure to start us off with the conference here with certainly one of the more uplifting stories, I think, in all of biotech, but joining me today from Amicus Therapeutics is Daphne Quimi and Jeff Castelli. Thank you so much for joining us.
Jeffrey P. Castelli
Amicus Therapeutics, Inc. - Chief Portfolio Officer & Head of Gene Therapy
Thank you.
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
My name is Jason Zemansky. I am an associate on Geoff Meacham's team, large cap biopharma analyst at Barclays.
So I think we should just dive into the questions.
Questions & Answers
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
So certainly, a large milestone in Amicus' story was the commercial approval of Galafold last August. Can you tell us a little bit about the feedback
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot